An Optimal Mechanism to Fund the Development of Vaccines Against Emerging Epidemics
Author
Abstract
Suggested Citation
Note: DEV EH IO LE PR
Download full text from publisher
As the access to this document is restricted, you may want to look for a different version below or search for a different version of it.
Other versions of this item:
- Snyder, Christopher M. & Hoyt, Kendall & Gouglas, Dimitrios, 2023. "An optimal mechanism to fund the development of vaccines against emerging epidemics," Journal of Health Economics, Elsevier, vol. 91(C).
References listed on IDEAS
- DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
- Geoffard, Pierre-Yves & Philipson, Tomas, 1997. "Disease Eradication: Private versus Public Vaccination," American Economic Review, American Economic Association, vol. 87(1), pages 222-230, March.
- Chari, V.V. & Golosov, Mikhail & Tsyvinski, Aleh, 2012.
"Prizes and patents: Using market signals to provide incentives for innovations,"
Journal of Economic Theory, Elsevier, vol. 147(2), pages 781-801.
- V. V. Chari & Mikhail Golosov & Aleh Tsyvinski, 2009. "Prizes and patents: using market signals to provide incentives for innovations," Working Papers 673, Federal Reserve Bank of Minneapolis.
- V. V. Chari & Mikhail Golosov & Aleh Tsyvinski, 2009. "Prizes and Patents: Using Market Signals to Provide Incentives for Innovations," Levine's Working Paper Archive 814577000000000398, David K. Levine.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Glenn Ellison & Sara Fisher Ellison, 2011.
"Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration,"
American Economic Journal: Microeconomics, American Economic Association, vol. 3(1), pages 1-36, February.
- Glenn Ellison & Sara Fisher Ellison, 2007. "Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration," NBER Working Papers 13069, National Bureau of Economic Research, Inc.
- Fan, Victoria Y & Jamison, Dean T & Summers, Lawrence H, 2018. "Pandemic risk: how large are the expected losses?," Scholarly Articles 35014363, Harvard Kennedy School of Government.
- Mark Bagnoli & Ted Bergstrom, 2006.
"Log-concave probability and its applications,"
Studies in Economic Theory, in: Charalambos D. Aliprantis & Rosa L. Matzkin & Daniel L. McFadden & James C. Moore & Nicholas C. Yann (ed.), Rationality and Equilibrium, pages 217-241,
Springer.
- Mark Bagnoli & Ted Bergstrom, 2005. "Log-concave probability and its applications," Economic Theory, Springer;Society for the Advancement of Economic Theory (SAET), vol. 26(2), pages 445-469, August.
- Bagnoli, M. & Bergstrom, T., 1989. "Log-Concave Probability And Its Applications," Papers 89-23, Michigan - Center for Research on Economic & Social Theory.
- Declan Butler, 2017. "Billion-dollar project aims to prep vaccines before epidemics hit," Nature, Nature, vol. 541(7638), pages 444-445, January.
- Aadhaar Chaturvedi & Victor Martínez-de-Albéniz, 2011. "Optimal Procurement Design in the Presence of Supply Risk," Manufacturing & Service Operations Management, INFORMS, vol. 13(2), pages 227-243, May.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Susan Athey & Juan Camilo Castillo & Esha Chaudhuri & Michael Kremer & Alexandre Simoes Gomes & Christopher M Snyder, 2022.
"Expanding capacity for vaccines against Covid-19 and future pandemics: a review of economic issues [‘Seven Finance & Trade Lessons from COVID-19 for Future Pandemics’],"
Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, vol. 38(4), pages 742-770.
- Susan Athey & Juan Camilo Castillo & Esha Chaudhuri & Michael Kremer & Alexandre Simoes Gomes & Christopher Snyder, 2022. "Expanding Capacity for Vaccines Against Covid-19 and Future Pandemics: A Review of Economic Issues," NBER Working Papers 30192, National Bureau of Economic Research, Inc.
- Michael Kremer & Christopher M. Snyder & Jonathan Levin, 2023. "Authors' response to Unjournal evaluations of "Advance Market Commitments: Insights from Theory and Practice"," The Unjournal Evaluations 2023-25, The Unjournal.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
- Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
- Fabian Gaessler & Stefan Wagner, 2022.
"Patents, Data Exclusivity, and the Development of New Drugs,"
The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
- Gaessler, Fabian & Wagner, Stefan, 2019. "Patents, Data Exclusivity, and the Development of New Drugs," Rationality and Competition Discussion Paper Series 176, CRC TRR 190 Rationality and Competition.
- Farasat A. S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2021.
"Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions,"
Small Business Economics, Springer, vol. 57(1), pages 603-634, June.
- Farasat A.S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2019. "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2016-01v3, Centre for Competition Policy, University of East Anglia, Norwich, UK..
- Aadhaar Chaturvedi & Damian R. Beil & Victor Martínez-de-Albéniz, 2014. "Split-Award Auctions for Supplier Retention," Management Science, INFORMS, vol. 60(7), pages 1719-1737, July.
- Michael Kremer & Heidi Williams, 2010.
"Incentivizing Innovation: Adding to the Tool Kit,"
NBER Chapters, in: Innovation Policy and the Economy, Volume 10, pages 1-17,
National Bureau of Economic Research, Inc.
- Michael Kremer & Heidi Williams, 2010. "Incentivizing Innovation: Adding to the Tool Kit," Innovation Policy and the Economy, University of Chicago Press, vol. 10(1), pages 1-17.
- Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
- Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016.
"Late-stage pharmaceutical R&D and pricing policies under two-stage regulation,"
Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
- Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
- Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022.
"The economics of medical procedure innovation,"
Journal of Health Economics, Elsevier, vol. 81(C).
- David Dranove & Craig Garthwaite & Christopher Heard & Bingxiao Wu, 2021. "The Economics of Medical Procedure Innovation," NBER Working Papers 29438, National Bureau of Economic Research, Inc.
- Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
- Mehmet Ugur & Eshref Trushin, 2023.
"Information asymmetry, risk aversion and R&D subsidies: effect-size heterogeneity and policy conundrums,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 32(8), pages 1190-1215, November.
- Ugur, Mehmet & Trushin, Eshref, 2021. "Information asymmetry, risk aversion and R&D subsidies: Effect-size heterogeneity and policy conundrums," Greenwich Papers in Political Economy 32224, University of Greenwich, Greenwich Political Economy Research Centre.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022.
"Bargaining and International Reference Pricing in the Pharmaceutical Industry,"
Research Papers
3889, Stanford University, Graduate School of Business.
- Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," NBER Working Papers 30053, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 22-1338, Toulouse School of Economics (TSE).
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," CEPR Discussion Papers 17293, C.E.P.R. Discussion Papers.
- Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
- Kristopher J. Hult, 2017. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments," NBER Working Papers 23900, National Bureau of Economic Research, Inc.
- Banerjee, Tannista & Siebert, Ralph, 2017. "Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry," Research Policy, Elsevier, vol. 46(7), pages 1255-1271.
- Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015.
"Market size and pharmaceutical innovation,"
RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
- Seabright, Paul & Scott Morton, Fiona & Dubois, Pierre & de Mouzon, Olivier, 2011. "Market Size and Pharmaceutical Innovation," CEPR Discussion Papers 8367, C.E.P.R. Discussion Papers.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," TSE Working Papers 11-232, Toulouse School of Economics (TSE), revised Mar 2014.
- Matthew J. Higgins & Mathias J. Kronlund & Ji Min Park & Joshua Pollet, 2020. "The Role of Assets In Place: Loss of Market Exclusivity and Investment," NBER Working Papers 27588, National Bureau of Economic Research, Inc.
- Joshua Krieger & Danielle Li & Dimitris Papanikolaou, 2022.
"Missing Novelty in Drug Development,"
The Review of Financial Studies, Society for Financial Studies, vol. 35(2), pages 636-679.
- Joshua L. Krieger & Danielle Li & Dimitris Papanikolaou, 2018. "Missing Novelty in Drug Development," NBER Working Papers 24595, National Bureau of Economic Research, Inc.
- Aadhaar Chaturvedi & Elena Katok & Damian R. Beil, 2019. "Split-Award Auctions: Insights from Theory and Experiments," Management Science, INFORMS, vol. 65(1), pages 71-89, January.
More about this item
JEL classification:
- D47 - Microeconomics - - Market Structure, Pricing, and Design - - - Market Design
- H44 - Public Economics - - Publicly Provided Goods - - - Publicly Provided Goods: Mixed Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
- O31 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Innovation and Invention: Processes and Incentives
NEP fields
This paper has been announced in the following NEP Reports:- NEP-CTA-2022-12-05 (Contract Theory and Applications)
- NEP-DES-2022-12-05 (Economic Design)
- NEP-HEA-2022-12-05 (Health Economics)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:30619. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.